Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin Adverse events · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin Hospitalisations · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin New acquisition of CF pathogens: PA · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin Need for additional antibiotics · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin QoL · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin Pulmonary exacerbations: time to next exacerbation · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin Hospitalisations · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin Need for additional antibiotics · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ weekly azithromycin vs daily azithromycin New acquisition of CF pathogens: PA · adults and children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ weekly azithromycin vs daily azithromycin Need for additional antibiotics · adults and children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo QoL of participants living with SCD and their caregivers · children and adults with sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Adverse effects · children and adults with sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Frequency of hospitalization · children and adults with sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
L‐arginine vs placebo QoL of participants living with SCD and their caregivers · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
L‐arginine vs placebo Frequency of sickle cell‐related complications · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo Frequency of crisis · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Vitamin C 1400 mg plus vitamin E 800 mg vs placebo QoL of participants living with SCD and their caregivers · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD) Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo Severity of pain · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo QoL of participants living with SCD and their caregivers · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo Frequency of hospitalization · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo Frequency of sickle cell‐related complications · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Vitamin C 1400 mg plus vitamin E 800 mg vs placebo Frequency of hospitalization · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD) Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Severity of pain · children and adults with sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for airway clearance techniques vs no airway clearance techniques Exacerbation rate (number of exacerbations/year) · children and adults with cystic fibrosis Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for airway clearance techniques vs no airway clearance techniques Exercise tolerance (MSWT) · children and adults with cystic fibrosis Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for airway clearance techniques vs no airway clearance techniques Well‐being or QoL · children and adults with cystic fibrosis Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline 3% to 7% vs isotonic saline LCI · adults and children with cystic fibrosis (during acute exacerbations of lung disease) Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline 3% to 7% vs isotonic saline Measures of sputum clearance · adults and children with cystic fibrosis (during acute exacerbations of lung disease) Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs rhDNase with LCI · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs rhDNase with Mortality · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs rhDNase with Measures of sputum clearance · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs amiloride FEV1: change from baseline, short‐term · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs amiloride FEV1: change from baseline, long‐term · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs amiloride LCI · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs amiloride Mortality · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs amiloride Pulmonary exacerbations · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs amiloride Adverse events · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®) FEV1: short‐term · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®) FEV1: long‐term · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®) LCI · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®) Mortality · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs mannitol FEV1: long‐term · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs mannitol LCI · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs mannitol Mortality · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline 3% to 7% vs isotonic saline Mortality · adults and children with cystic fibrosis (stable lung disease) Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline vs mannitol Pulmonary exacerbations · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline 7% vs xylitol FEV1 (% predicted) change from baseline, long‐term · adults with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline 7% vs xylitol LCI · adults with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline 7% vs xylitol Mortality · adults with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypertonic saline 7% vs xylitol Measures of sputum clearance · adults with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |